Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Survivorship in Patients Receiving Immune Checkpoint Inhibitors

Miscellaneous

Miscellaneous
N/A
Johnson, Douglas
VICCMEL15138

An Open-Label, Dose-Escalation / Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies

Multiple Cancer Types

This is an open-label, dose-escalation / dose-expansion study of INCB059872 in subjects with advanced malignancies. The study will be conducted in 4 parts. Part 1 (mono therapy dose escalation) will determine the recommended dose(s) of INCB059872 for dose expansion, based on maximum tolerated dose and / or a tolerated pharmacologically active dose. Part 2 (dose expansion) will further determine the safety, tolerability, efficacy, PK, and PD of the selected monotherapy dose(s) in AML / MDS, SCLC, myelofibrosis, Ewing sarcoma, and poorly differentiated neuroendocrine tumors. Part 3 will determine the recommended dose(s) of INCB059872 in combination with azacitadine and all-trans retinoic acid in AML and in combination with nivolumab in SCLC. Part 4 will further determine the safety, tolerability, efficacy, PK, and PD of the selected combination dose(s) in Part 3.
Hematologic, Leukemia, Lung, Miscellaneous, Small Cell
I/II
Savona, Michael
NCT02712905
VICCHEMP1615

Carvedilol in Preventing Heart Failure in Childhood Cancer Survivors

Multiple Cancer Types

This randomized phase IIb trial studies how well low-dose carvedilol works in preventing heart failure in cancer survivors exposed to high dose anthracyclines for management of childhood cancer. Patients who received high-dose anthracycline chemotherapy are at a much greater risk for developing heart failure compared to survivors who didn’t get any anthracycline chemotherapy. Heart failure happens when the heart muscle has been weakened and can’t pump blood as well as it should. Carvedilol may help lower the risk of cardiovascular complications.
Miscellaneous, Pediatrics
II
Friedman, Debra
NCT02717507
COGALTE1621

My Pathway: A Study Evaluating Herceptin / Perjeta, Tarceva, Zelboraf / Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

Miscellaneous

This multicenter, non-randomized, open-label study will evaluate the efficacy and safety of six treatment regimens in participants with advanced solid tumors for whom therapies that will convey clinical benefit are not available and / or are not suitable options per the treating physician's judgment.
Miscellaneous
II
Davis, Elizabeth
NCT02091141
VICCMD16103

VX-970 and Irinotecan Hydrochloride in Treating Patients with Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Miscellaneous

This phase I trial studies the side effects and best dose of VX-970 and irinotecan hydrochloride in treating patients with solid tumors that have spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable). VX-970 and irinotecan hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Miscellaneous
I
Davis, Elizabeth
NCT02595931
VICCPHI16154ET-CT

Inherited CAncer REgistry (ICARE) Initiative

Miscellaneous

Miscellaneous
N/A
Pal, Tuya
NCT03231891
VICCMD1712

Donating Tissues for Research

Miscellaneous

Miscellaneous
N/A
Washington, Mary Kay
VICCBIO0478

Key Adverse Events after Childhood Cancer

Multiple Cancer Types

Miscellaneous, Pediatric Leukemia, Pediatrics
N/A
Friedman, Debra
NCT00082745
COGALTE03N1

Long Term Effects for Childhood Cancer Survivors

Multiple Cancer Types

Miscellaneous, Pediatrics
N/A
Esbenshade, Adam
VICCPED0710

Neuropsychological and Behavioral Testing in Younger Patients with Cancer

Multiple Cancer Types

This research trial studies neuropsychological (learning, remembering or thinking) and behavioral outcomes in children and adolescents with cancer by collecting information over time from a series of tests.
Miscellaneous, Neuro-Oncology, Pediatrics
N/A
Friedman, Debra
NCT00772200
COGALTE07C1

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: